Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for vTv Therapeutics Inc. (VTVT : NSDQ)

• Company Description    vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $23.40 Daily Weekly Monthly 20 Day Moving Average: 4,764 shares Shares Outstanding: 3.94 (millions) Market Capitalization: $92.15 (millions) Beta: 0.66 52 Week High: $26.99 52 Week Low: $12.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.59% 1.90% 12 Week 51.23% 40.67% Year To Date 69.46% 45.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3980 PREMIER DR SUITE 310 - HIGH POINT,NC 27265 USA ph: 336-841-0300 fax: 336-841-0310 ir@vtvtherapeutics.com http://www.vtvtherapeutics.com

• General Corporate Information    Officers Paul J. Sekhri - President; Chief Executive Officer and Executive C Steven Tuch - Executive Vice President and Chief Financial Offic Richard Nelson - Director and Executive Vice President; Corporate D Anne M. Phillips - Director Daniel K. Spiegelman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 918385204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 3.94 Most Recent Split Date: 11.00 (0.03:1) Beta: 0.66 Market Capitalization: $92.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 31.08 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -13.58% vs. Previous Quarter: -19.48% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -179.75 03/31/25 - -121.46 ROA 09/30/25 - - 06/30/25 - -55.91 03/31/25 - -46.75 Current Ratio 09/30/25 - - 06/30/25 - 4.98 03/31/25 - 7.39 Quick Ratio 09/30/25 - - 06/30/25 - 4.98 03/31/25 - 7.39 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -140,435.28 03/31/25 - -134,723.52 Book Value 09/30/25 - - 06/30/25 - 0.75 03/31/25 - 2.79 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©